SCHEMBL4881623

SCHEMBL4881623

CC(C)(C)[Si](C)(C)OCCNc1ccc(-n2cnc(C(=O)Nc3ccc(Cl)cn3)c2C(N)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 5/20 0.36
NPC1 O15118 3/20 0.36
ALDH1A1 P00352 2/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
LMNA P02545 1/20 0.36
CASP3 P42574 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
F10 P00742 2/20 0.36
HTT P42858 1/20 0.35
TSHR P16473 3/20 0.35
SCN9A Q15858 3/20 0.35
GRM5 P41594 1/20 0.35
RIPK1 Q13546 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882261 0.93 SCN9A (0.41) RAB9ANPC1ALDH1A1LMNANPSR1
SCHEMBL4878069 0.84 SMN1; SMN2 (0.35) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL4710501 0.83 RAB9A (0.42) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL4875148 0.79 RAB9A (0.41) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL4880920 0.78 SCN9A (0.38) RAB9ANPC1ALDH1A1LMNANPSR1
SCHEMBL14066580 0.77 MAPT (0.53) SMN1; SMN2ALDH1A1NPSR1POLBMEN1
SCHEMBL4873941 0.75 GRM5 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL14066579 0.75 GRM5 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL4877155 0.75 F10 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1
SCHEMBL4878300 0.75 F10 (0.38) SMN1; SMN2RAB9ANPC1ALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 SMN1; SMN2 2534/4885RAB9A 2655/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.